Planforge Introduces Product Maturity Level Tracking with New Gate Management Option
13.2.2025 14:30:00 CET | Business Wire | Press release
Release 25 Also Introduces First GenAI-Powered Assistant Features and Configurable Portfolio Dashboards
Planforge today announced Planforge 25, the latest release of its industry-leading project work management software. The new version introduces the Gate Management Option (GMO), an optional module developed specifically to help track the product maturity level for development projects. With version 25, Planforge also ships their first GenAI-powered assistant features as announced late last year. The release also features more configurable portfolio dashboards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213182628/en/
Planforge 25: New Gate Management Option enables seamless product maturity tracking in development projects. (Graphic: Business Wire)
Gate Management for Development Projects
With its new Gate Management Option, Planforge builds a bridge between development processes and projects by directly integrating support for process gates into project planning. A process gate is a key decision point in a workflow where progress is evaluated to ensure criteria are met before moving to the next phase. Gates are uniquely defined on the project pipeline stage level, and can then be used in project templates and plans together with progress criteria and due dates.
Process gate criteria are based on work packages (WP) and target progress levels per WP. Therefore, the maturity level per criterion can be automatically derived based on actual WP progress. Process gate maturity levels are in turn aggregated based on criteria progress levels. Also target dates for process gates can be automatically monitored based on actual versus planned finish dates of their linked work packages.
"In the technology and automotive industries, gate management today involves a lot of manual work, as project plans are not integrated with process gates in any way," said Gerald Aquila, founder & CEO of Planforge. "With Planforge 25, we are changing the game: by directly reusing existing actual project management data for monitoring and controlling process gates we can not only save many hours of work, but also cut administrative costs significantly."
Additionally, Planforge now integrates a simple but powerful gate review process where go/no-go decisions, gate revisions, and required measures can be easily tracked in a revision-safe way. This allows for early warnings and delivers more transparency and more insightful KPIs. All gate-related information is clearly summarised in dedicated new views for gates planning and controlling, covering single and multiple projects alike.
First Assistant Features of GenAI Initiative
Planforge 25 further introduces the first assistant features of the company’s broader GenAI initiative. For instance, project managers can ask the system for suggestions for SMART (specific, measurable, achievable, realistic and time-bound) project objectives based on the current project description and additional related meta data such as linked ideas. These functions are context-sensitive, directly embedded in the main user interface (in this case, the project charter) and currently powered by OpenAI's ChatGPT.
Configurable Portfolio Dashboards
After introducing custom KPIs and configurable KPI overviews last year, Planforge 25 now also makes portfolio dashboards configurable. Just like for the KPIs view, users can now easily configure the displayed widgets via drag and drop per portfolio.
Availability
Planforge is free for up to four users. Larger teams can test the project work management software via a free 30-day trial. For more information or to be among the first to try the new Gate Management Option, please contact the Planforge sales team at info@planforge.io.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213182628/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom